Bayer And CRISPR Form Cutting Edge Gene Editing JV
This article was originally published in Scrip
Executive Summary
A big pharma has entered the fray, teaming up with a biotech to create the first long-term stand-alone joint venture exploring the gene-editing technology Crispr-Cas9. German conglomerate Bayer AG and Switzerland-based CRISPR Therapeutics have created a joint venture that will explore the technology in three therapeutic areas.
You may also be interested in...
Finance Watch: Billions In And Billions Out In Venture Capital Fundraising
Private Company Edition: The flood of venture capital into health care and life science firms continues with Perceptive closing a $1.1bn credit fund and Sanofi investing $50m in Jeito Capital. Also, Ambrx closed a $200m crossover round as biopharma remains on track for a record funding year.
Novo Nordisk, Bluebird Targeting ‘Lifelong’ Gene Therapies
Novo Nordisk and bluebird bio will jointly develop genome editing treatments for genetic diseases, beginning with hemophilia.
Versant's Century Aims For Off-The-Shelf Cancer Cell Therapies
With Bayer’s venture arm providing $215m, Versant Ventures’ Century Therapeutics emerges with $250m and a plan to develop allogeneic stem cell therapies for various cancers, including solid tumors.